Albert Bourla, Pfizer CEO (Matthew Busch/Bloomberg via Getty Images)
July 15, 2022 01:47 PM EDTUpdated 02:45 PM
Pharma
FDA+

Pfiz­er cel­e­brates a new FDA ap­proval as the Xalko­ri fran­chise slow­ly winds down

John Carroll

Editor & Founder

Sales of Pfiz­er’s Xalko­ri may be slip­ping as new drugs squeeze the on­col­o­gy mar­ket, but the phar­ma gi­ant hasn’t lost its ap­petite for new in­di­ca­tions …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Io­n­is’ treat­ment for a rare meta­bol­ic dis­or­der

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times